Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Eli Lilly Rises After FDA Approval for Once-Weekly Diabetes Insulin

None

Eli Lilly and Company (LLY) is up 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is FDA approval of Onswik, Lilly’s once-weekly basal insulin for adults with type 2 diabetes. Investors appear to be responding to the added growth opportunity in diabetes care and the potential appeal of a treatment that can reduce injection frequency versus daily basal insulin.

Details:

  • Lilly announced on September 24, 2026 that the FDA approved Onswik, also known as insulin efsitora alfa-gobe, for adults with type 2 diabetes.
  • The company said the product is designed to provide steady basal insulin coverage over seven days, giving patients an alternative to once-daily long-acting insulin injections.
  • Lilly said the approval was supported by the Phase 3 QWINT program, which studied more than 3,400 adults with type 2 diabetes and met the main efficacy goal across the trials.
  • The new approval broadens Lilly’s diabetes portfolio at a time when the company is already viewed as a major player in cardiometabolic treatments, which may be reinforcing bullish sentiment around its longer-term franchise.
  • Sources:

    Eli Lilly and Company, FDA, Reuters

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $LLY Insider Trading Activity

    LLY Insider Trades

    $LLY insiders have traded $LLY stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

    Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:

    • PATRIK JONSSON (EVP & President, LLY Int'l) sold 6,500 shares for an estimated $7,638,149
    • ANAT HAKIM (EVP, GC & Secretary) sold 5,000 shares for an estimated $5,950,000
    • ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares for an estimated $2,876,925
    • DONALD A ZAKROWSKI (SVP, Finance, & CAO) sold 2,000 shares for an estimated $2,370,020

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    EARLY ACCESS
    Receive LLY Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $LLY Hedge Fund Activity

    We have seen 2,578 institutional investors add shares of $LLY stock to their portfolio, and 1,716 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $LLY Congressional Stock Trading

    Members of Congress have traded $LLY stock 8 times in the past 6 months. Of those trades, 4 have been purchases and 4 have been sales.

    Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:

    To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

    $LLY Price Targets

    Multiple analysts have issued price targets for $LLY recently. We have seen 11 analysts offer price targets for $LLY in the last 6 months, with a median target of $1350.0.

    Here are some recent targets:

    • Trung Huynh from RBC Capital set a target price of $1500.0 on 07/08/2026
    • Robyn Karnauskas from Truist Securities set a target price of $1370.0 on 07/08/2026
    • Terence Flynn from Morgan Stanley set a target price of $1347.0 on 07/08/2026
    • Chris Schott from JP Morgan set a target price of $1400.0 on 07/07/2026
    • Carter Gould from Cantor Fitzgerald set a target price of $1350.0 on 07/06/2026
    • David Risinger from Leerink Partners set a target price of $1232.0 on 06/25/2026
    • Akash Tewari from Jefferies set a target price of $1350.0 on 06/09/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles